<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>70-ANTI-TNF-ALPHA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTI-TNF ALPHA" code="LO4AB" /></DRUG1>
<DRUG2>
<DRUG name="ABATACEPT " rxcui="614391">
<ATC code="L04AA24" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the immunodepression </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>70-ANTI-TNF-ALPHA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTI-TNF ALPHA" code="LO4AB" /></DRUG1>
<DRUG2>
<DRUG name="ANAKINRA" rxcui="72435">
<ATC code="L04AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of serious infections and neutropenia</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>70-ANTI-TNF-ALPHA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTI-TNF ALPHA" code="LO4AB" /></DRUG1>
<DRUG2>
<DRUG name="CANAKINUMAB" rxcui="853491">
<ATC code="L04AC08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of serious infections</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>70-ANTI-TNF-ALPHA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTI-TNF ALPHA" code="LO4AB" /></DRUG1>
<DRUG2>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG2>
<DESCRIPTION>Risk of general vaccine disease possibly fatal</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>And during the 3 months following the end of the treatment.</COMMENT>
</INTERACTION>
</INTERACTIONS>
